|Bid||101.55 x 800|
|Ask||101.96 x 1000|
|Day's range||101.75 - 102.70|
|52-week range||68.93 - 106.51|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||17.96|
|Earnings date||19 Oct 2021|
|Forward dividend & yield||5.00 (4.86%)|
|Ex-dividend date||28 Sept 2021|
|1y target est||109.69|
Philip Morris (PM) secures more than 74% of Vectura's shares to become a majority stakeholder. The company expects to amplify growth in its Beyond Nicotine strategy via this move.
British inhaler developer Vectura has been barred from a major medical conference amid a growing backlash over its £1bn takeover by tobacco giant Philip Morris International.
Philip Morris (PM) buys Fertin Pharma to attain its target of becoming a majority smoke-free company by 2025. The company also raises its quarterly dividend.